c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia

Chronic myeloid leukemia (CML) is a malignant disease of the primitive hematologic cell which is driven by BCR-ABL1 tyrosine kinase activity.[1][1] Although in recent years CML treatment has been drastically improved by the tyrosine kinase inhibitor (TKI) imatinib, at least one-third of patients